Update for primary healthcare providers: Recent statin trials and revised national cholesterol education program III guidelines

MedGenMed Medscape General Medicine

Volumn 8, Issue 1, 2006, Pages

  Hennekens, Charles H ^a,b,c   Hollar, Danielle ^a,b,c   Eidelman, Rachel S ^d,e   Agatston, Arthur S ^a,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c Agatston Research Institute   (United States)

^d Florida Cardiology Group   (United States)

^e Agatston Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL DISEASE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DRUG FATALITY; EDUCATION PROGRAM; FEVER; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; META ANALYSIS; METABOLIC SYNDROME X; MYALGIA; MYOPATHY; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROTEINURIA; PUBLISHING; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; THORAX PAIN; CONTROLLED CLINICAL TRIAL; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIAL;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS;

EID: 33644540801     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278:313-321. Abstract.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. Abstract.
3. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. Abstract.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. Abstract.
5. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630. Abstract.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007. Abstract.
7. Hennekens CH; The ALLHAT-LLT and ASCOT-LLA Trials. Are the discrepancies more apparent than real? Curr Atherosclerosis Rep. 2004;6:9-11.
8. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. Abstract.
9. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080. Abstract.
10. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. Abstract.
11. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696. Abstract.
12. Zipes DP, Pfeffer MA,, Zvaifler NJ, et al. Analysis of the efficacy and safety of rosuvastatin. MedGenMed. In press.
13. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists'(CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278. Abstract.